We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
-22.31%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$139M
AUM Growth
-$88.9M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
12.5 quarters
Top 10 Avg Time Held
12.5 quarters
Top 20 Avg Time Held
12.5 quarters

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BHVN icon
1
Biohaven
BHVN
$1.78B
$70.6M 50.84%
2,936,507
– –
2022 Q4
9 quarters
CYTK icon
2
Cytokinetics
CYTK
$8.77B
$39.4M 28.38%
980,392
– –
2024 Q2
3 quarters
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.14B
$28.8M 20.78%
3,846,154
– –
2021 Q4
13 quarters
VIRX icon
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$74 ﹤0.01%
3,700
– –
2018 Q4
25 quarters

Similar funds

RP Management's Q1 2025 Portfolio in Review

As of Q1 2025, RP Management held 4 positions worth $139M, down 39% from $228M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 0%. RP Management opened no new positions and made no exits, leaving the 4-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • RP Management's ten largest holdings make up 100% of its $139M portfolio in Q1 2025.
  • RP Management opened 0 new positions and closed 0 in Q1 2025.
  • RP Management's portfolio value fell 39% quarter-over-quarter to $139M.

Based on RP Management's 13F filing for Q1 2025, filed 2 May 2025.